ReviewDiabetes, obesity & metabolism2016

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

M NauckPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.